Sociodemographic features predict antidepressant trajectories of response in diverse antidepressant pharmacotreatment environments: A comparison between the STAR*D study and an independent trial

Journal of Clinical Psychopharmacology

Volumn 31, Issue 3, 2011, Pages 345-348

  Drago, Antonio ^a   Serretti, Alessandro ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

antidepressant; depression; pharmacotreatment; predictors of response

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; FLUVOXAMINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGED; ARTICLE; DEMOGRAPHY; DEPRESSION; DRUG RESPONSE; ENVIRONMENT; FEMALE; HUMAN; ILLNESS TRAJECTORY; ITALY; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; PREDICTION; PREDICTOR VARIABLE; PRIORITY JOURNAL;

ADULT; ANTIDEPRESSIVE AGENTS; CROSS-CULTURAL COMPARISON; DEMOGRAPHY; DEPRESSIVE DISORDER, MAJOR; ENVIRONMENT; FEMALE; HUMANS; ITALY; MALE; MIDDLE AGED; MODELS, STATISTICAL; SEVERITY OF ILLNESS INDEX; UNITED STATES;

EID: 79955631873     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3182189c64     Document Type: Article

References (13)

1. Arranz MJ, Kapur S. Pharmacogenetics in psychiatry: are we ready for widespread clinical use? Schizophr Bull. 2008;34(6):1130-1144.
2. Nierenberg AA. Predictors of response to antidepressants general principals and clinical implications. Psychiatr Clin North Am. 2003;26:345-352. (Pubitemid 36583567)
3. Gaynes BN, Warden D, Trivedi MH, et al. What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. Psychiatr Serv. 2009;60(11):1439-1445.
4. Rush AJ, Warden D, Wisniewski SR, et al. STAR*D: revising conventional wisdom. CNS Drugs. 2009;23(8):627-647.
5. Rush AJ,Wisniewski SR,Warden D, et al. Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features. Arch Gen Psychiatry. 2008;65(8):870-880.
6. Serretti A, Calati R, Oasi O, et al. Dissecting the determinants of depressive disorders outcome: an in depth analysis of two clinical cases. Ann Gen Psychiatry. 2007;6:5.
7. Serretti A, Lorenzi C, Cusin C, et al. SSRIs antidepressant activity is influenced by Gbeta3 variants. Eur Neuropsychopharmacol. 2003;13(2):117-122. (Pubitemid 36313286)
8. Serretti A, Olgiati P, Liebman MN, et al. Clinical prediction of antidepressant response in mood disorders: linear multivariate vs. neural network models. Psychiatry Res. 2007;152(2-3):223-231. (Pubitemid 47212479)
9. Gildengers AG, Houck PR, Mulsant BH, et al. Trajectories of treatment response in late-life depression: psychosocial and clinical correlates. J Clin Psychopharmacol. 2005;25(4 suppl 1):S8-S13. (Pubitemid 41060240)
10. Uher R, Muthen B, Souery D, et al. Trajectories of change in depression severity during treatment with antidepressants. Psychol Med. 2010;40(8):1367-1377.
11. Papakostas GI, Perlis RH, Scalia MJ, et al. A meta-analysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorder. J Clin Psychopharmacol. 2006;26(1):56-60. (Pubitemid 43167092)
12. Deshauer D, Moher D, Fergusson D, et al. Selective serotonin reuptake inhibitors for unipolar depression: a systematic reviewof classic long-term randomized controlled trials. CMAJ. 2008;178(10):1293-1301. (Pubitemid 351678352)
13. Serretti A, Kato M, De Ronchi D, et al. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry. 2007;12(3):247-257. (Pubitemid 46328503)